Welcome to the international HTA database

Showing [22278 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2022	National Institute for Health and Care Excellence (NICE)	Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea. NICE technology appraisal guidance 776
2022	Health Information and Quality Authority (HIQA)	COVID-19 Evidence Synthesis: International review of guidance on the use of face masks to mitigate the spread of SARS-CoV-2 infection
2022	National Institute for Health and Care Excellence (NICE)	Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea. NICE technology appraisal guidance 777
2022	NIHR Health Technology Assessment programme	Antibiotics for lower respiratory tract infection in children presenting in primary care (ARTIC PC)
2022	Health Technology Wales (HTW)	Video laryngoscopes for use in pre-hospital care
2022	National Institute for Health and Care Excellence (NICE)	Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria. NICE technology appraisal guidance 778
2022	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Cardiac monitoring with textile wearable Holter for atrial fibrillation detection after cryptogenic stroke]
2022	National Institute for Health and Care Excellence (NICE)	Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 779
2022	WorkSafeBC	N-acetylcysteine (NAC) as treatment for complex regional pain syndrome (CRPS): 2022 Update
2022	National Institute for Health and Care Excellence (NICE)	Nivolumab with ipilimumab for untreated advanced renal cell carcinoma. NICE technology appraisal guidance 780
2022	NIHR Health Technology Assessment programme	Evaluation of the Healthy Start Voucher Scheme in UK: a natural experiment using the Growing Up in Scotland record linkage study and the Infant Feeding Survey
2022	Canadian Agency for Drugs and Technologies in Health (CADTH)	Peer support programs for youth mental health
2022	WorkSafeBC	Antalgic gait, limp, osteoarthritis - what happens to the weight-bearing joints?
2022	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Use of indocyanine green in colorectal and hepato-biliopancreatic surgery]
2022	National Institute for Health and Care Excellence (NICE)	Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 781
2022	WorkSafeBC	SANUWAVE therapy for wound healing
2022	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Evaluation of several vaccination strategies against rotavirus in Spain. Safety, efficacy, effectiveness and efficiency]
2022	National Institute for Health and Care Excellence (NICE)	Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal). NICE technology appraisal guidance 782
2022	NIHR Health Technology Assessment programme	DexEnceph- Dexamethasone in Herpes Simplex Virus Encephalitis Randomised Controlled Trial and NonHSV Cohort Study
2022	Canadian Agency for Drugs and Technologies in Health (CADTH)	Treatment of adult patients with immune thrombocytopenia after failure of first-line therapies
2022	WorkSafeBC	Balloon spacer as treatment for massive rotator cuff tear
2022	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Efficacy and safety of transanal irrigation in adults with bowel dysfunction]
2022	National Institute for Health and Care Excellence (NICE)	Daratumumab monotherapy for treating relapsed and refractory multiple myeloma. NICE technology appraisal guidance 783
2022	Canadian Agency for Drugs and Technologies in Health (CADTH)	Internet-delivered cognitive behavioural therapy in the treatment of chronic non-cancer pain
2022	WorkSafeBC	Satir brief transformational therapy as treatment for trauma-related disorders including PTSD
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: assessment of the relevance of tandem mass spectrometry-based newborn blood spot screening for argininosuccinic aciduria (ASA)]
2022	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Systematic review on diagnosis and care of reactive attachment disorder]
2022	National Institute for Health and Care Excellence (NICE)	Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer. NICE technology appraisal guidance 784
2022	Canadian Agency for Drugs and Technologies in Health (CADTH)	Intraocular lens implantation for infants with aphakia: a systematic review of clinical effectiveness and cost-effectiveness
2022	National Institute for Health and Care Excellence (NICE)	Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal). NICE technology appraisal guidance 785
2022	Norwegian Institute of Public Health (NIPH)	[Intravenous ketamine for treatment-resistant depression and suicidal ideation: a single technology assessment - mapping]
2022	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Safety and effectiveness of percutaneous tricuspid valve repair]
2022	National Institute for Health and Care Excellence (NICE)	Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies. NICE technology appraisal guidance 786
2022	NIHR Health Technology Assessment programme	The Best Services Trial (BeST?): Effectiveness and cost-effectiveness of the New Orleans Intervention Model for Infant Mental Health
2022	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Effectiveness of social distancing measures, in the context of the COVID-19]
2022	National Institute for Health and Care Excellence (NICE)	Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable. NICE technology appraisal guidance 787
2022	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Occupational exposures and asthma and COPD]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Treprostinil in chronic thromboembolic pulmonary hypertension (group 4)]
2022	The Regional Health Technology Assessment Centre (HTA-centrum)	Osseointegrated upper limb prostheses with and without neuromuscular control: benefits and risks
2022	National Institute for Health and Care Excellence (NICE)	Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy. NICE technology appraisal guidance 788
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Irreversible electroporation in pancreatic cancer]
2022	The Regional Health Technology Assessment Centre (HTA-centrum)	[Benefits and risks of caseload midwifery: continuity of midwifery team during antenatal, intrapartal, and postnatal care]
2022	National Institute for Health and Care Excellence (NICE)	Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations. NICE technology appraisal guidance 789
2022	NIHR Health Technology Assessment programme	Accuracy of a rapid intrapartum test for maternal group B streptococcal colonisation and its potential to reduce antibiotic usage in mothers with risk factors (GBS2)
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: integration of real-world data and evidence into assessments to support decision-making in the pharmaceutical sector]
2022	Austrian Institute for Health Technology Assessment (AIHTA)	Quality registries in dementia care: mapping of registries to improve quality and service delivery
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Digital breast tomosynthesis]
2022	The Regional Health Technology Assessment Centre (HTA-centrum)	Active or semi-active robotic arm-assisted versus manual knee arthroplasty: benefits and risks
2022	National Institute for Health and Care Excellence (NICE)	TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal). NICE technology appraisal guidance 790
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Medications for treating moderate to severe alcohol withdrawal syndrome in critical care and emergency department patients
2022	Malaysian Health Technology Assessment (MaHTAS)	Molecular profiling assays in early breast cancer
2022	The Regional Health Technology Assessment Centre (HTA-centrum)	Effectiveness and safety of surgical procedures to treat apical prolapse - comparison of sacrospinous fixation, laparoscopic sacrocolpopexy/sacrohysteropexy, and the Manchester procedure
2022	National Institute for Health and Care Excellence (NICE)	Romosozumab for treating severe osteoporosis. NICE technology appraisal guidance 791
2022	NIHR Health Technology Assessment programme	Paclitaxel assisted balloon Angioplasty of Venous stenosis in haEmodialysis access: The PAVE Trial. A multicentre double-blind randomised controlled trial in haemodialysis patients with a stenosis in a native arteriovenous fistula
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Guidelines and clinical pathways for management of upper GI bleeding
2022	Malaysian Health Technology Assessment (MaHTAS)	Immunotherapy for PD-L1 positive advanced non-small cell lung cancer
2022	National Institute for Health and Care Excellence (NICE)	Filgotinib for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 792
2022	NIHR Health Technology Assessment programme	Assessing the efficacy and safety of methotrexate vs ciclosporin in the treatment of severe atopic eczema in children: the TREatment of severe Atopic eczema in children Taskforce (TREAT) randomised controlled trial
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Peripartum or postnatal care disparities and equity
2022	Malaysian Health Technology Assessment (MaHTAS)	Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) for non-small cell lung cancer
2022	National Institute for Health and Care Excellence (NICE)	Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal). NICE technology appraisal guidance 793
2022	NIHR Health Technology Assessment programme	EarlyCDT Lung blood test for risk classification of solid pulmonary nodules: systematic review and economic evaluation
2022	Malaysian Health Technology Assessment (MaHTAS)	Robotic arm-assisted surgery in total hip arthroplasty, total knee arthroplasty and unicompartmental knee arthroplasty
2022	National Institute for Health and Care Excellence (NICE)	Diroximel fumarate for treating relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 794
2022	NIHR Health Technology Assessment programme	Prospective randomised marker-based trial to assess the clinical utility and safety of biomarker-guided immunosuppression withdrawal in liver transplantation (LiverTOL-Dx Trial)
2022	WorkSafeBC	Clinical accuracy of rapid antigen tests for COVID-19
2022	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Ambulatory blood pressure monitoring (ABPM) in the identification of circadian patterns in patients with arterial hypertension: evaluation of safety, effectiveness, and efficiency]
2022	National Institute for Health and Care Excellence (NICE)	Ibrutinib for treating Waldenstrom's macroglobulinaemia. NICE technology appraisal guidance 795
2022	NIHR Health Technology Assessment programme	Unspecified living kidney donation in the UK: barriers to implementation and delivery
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Workplace violence in healthcare settings
2022	WorkSafeBC	Functional neurology as treatment for post-traumatic brain injury
2022	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Evaluation of the safety, efficacy/effectiveness, and efficiency of teleconsultation in primary care, and the organizational, ethical, social, and legal aspects linked to its use]
2022	National Institute for Health and Care Excellence (NICE)	Venetoclax for treating chronic lymphocytic leukaemia. NICE technology appraisal guidance 796
2022	NIHR Health Technology Assessment programme	Delivering primary health care to homeless people: an evaluation of the integration, effectiveness and costs of different models
2022	Health Technology Wales (HTW)	Electronic blood management systems for blood transfusions
2022	WorkSafeBC	Dupuytren's contracture and wrist fractures
2022	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Evaluation of the safety, efficacy/effectiveness, and efficiency of stereotactic body radiation therapy (SBRT) in lung, prostate, and liver cancer]
2022	National Institute for Health and Care Excellence (NICE)	Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal). NICE technology appraisal guidance 797
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: evaluation of Synvisc and Synvisc One for the management of knee osteoarthritis]
2022	WorkSafeBC	Percussion therapy for neuropathic pain
2022	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Stereotactic radiosurgery for the treatment of epilepsy, essential tremor, Parkinson's disease, glossopharyngeal and trigeminal neuralgia: synthesis of its efficacy, effectiveness, safety, and efficiency]
2022	National Authority for Assessment and Accreditation in Healthcare (INEAS)	[SKYRIZI® (Risankizumab) for the treatment of moderate to severe plaque psoriasis in adults : A rapid review]
2022	National Institute for Health and Care Excellence (NICE)	Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation. NICE technology appraisal guidance 798
2022	NIHR Health Technology Assessment programme	The START (STrAtegies for RelaTives) study: a pragmatic randomised controlled trial to determine the effectiveness of a manual based coping strategy programme in promoting the mental health of carers of people with dementia - cohort follow-up
2022	NIHR Health Technology Assessment programme	Coenzyme Q10 to manage chronic heart failure with a reduced ejection fraction: a systematic review and economic evaluation
2022	WorkSafeBC	Ketamine infusion therapy for hyperalgesia and or central sensitivity pain
2022	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Primary bariatric endoscopic techniques in adults with or without type 2 diabetes mellitus. Efficacy, effectiveness, and safety]
2022	National Institute for Health and Care Excellence (NICE)	Faricimab for treating diabetic macular oedema. NICE technology appraisal guidance 799
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: use of electrodiagnostic testing in the neurological investigation - electromyography and nerve conduction studies]
2022	National Institute for Health and Care Excellence (NICE)	Faricimab for treating wet age-related macular degeneration. NICE technology appraisal guidance 800
2022	Health Technology Wales (HTW)	Stereotactic ablative radiotherapy (SABR) for the treatment of renal cell carcinoma
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: KamRAB (human rabies immunoglobulin) – passive and transient postexposure prophylaxis of rabies infection]
2022	National Institute for Health and Care Excellence (NICE)	Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer. NICE technology appraisal guidance 801
2022	NIHR Health Technology Assessment programme	Oral nutritional interventions in frail older people who are malnourished or at risk of malnutrition: a systematic review
2022	National Institute for Health and Care Excellence (NICE)	Cemiplimab for treating advanced cutaneous squamous cell carcinoma. NICE technology appraisal guidance 802
2022	NIHR Health Technology Assessment programme	Treatment of Barth Syndrome by CARDIOlipin MANipulation (CARDIOMAN): a randomised placebo-controlled pilot trial conducted by the nationally commissioned Barth Syndrome Service
2022	NIHR Health Technology Assessment programme	Determining optimal strategies for primary prevention of cardiovascular disease: systematic review of cost-effectiveness analyses in the United Kingdom
2022	National Institute for Health and Care Excellence (NICE)	Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs. NICE technology appraisal guidance 803
2022	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Home enteral nutrition in older patients with severe protein-energy malnutrition after hip fracture]
2022	NIHR Health Services and Delivery Research programme	Understanding the potential factors affecting carers’ mental health during end-of-life home care: a meta synthesis of the research literature